76 results
SC 14D9/A
EX-99
PNT
POINT Biopharma Global Inc.
18 Dec 23
Tender offer solicitation (amended)
8:14am
Communications
646-975-2533
media@lantheus.com
POINT Biopharma
Daniel Pearlstein
Director, Strategy
investors@pointbiopharma.com
SC 14D9
PNT
POINT Biopharma Global Inc.
13 Oct 23
Tender offer solicitation
7:11am
to strengthen POINT’s business and enhance value for its stockholders. From time to time, these reviews and evaluations have included POINT’s strategy … creation associated with those alternatives. As part of these evaluations, the POINT Board considered continuing to execute POINT’s strategy on a standalone
SC TO-T
EX-99
PNT
POINT Biopharma Global Inc.
13 Oct 23
Third party tender offer statement
6:52am
leadership roles with Lilly, including roles in research and development, engineering, manufacturing, strategy, business development, marketing, sales
SC14D9C
EX-99.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Written communication relating to third party tender offer
5:24pm
that can serve as the foundation for its oncology growth strategy, including radiopharmaceuticals. POINT’s team, infrastructure and capabilities stood out
8-K
EX-99.1
h0um8kckol8zfopea6u
14 Aug 23
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
7:21am
ARS
357miv 816pq
1 May 23
Annual report to shareholders
1:52pm
8-K
EX-99.1
fpwnhft2fnnbhw
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm
8-K
EX-99.1
xjatil9sqnkc6tub8
13 Sep 22
POINT Biopharma Announces Proposed Public Offering of Common Stock
4:12pm
8-K
EX-99.1
be3f g31xbys9
12 Sep 22
POINT Biopharma Provides Updated Efficacy and Safety Data from the Lead-In Cohort of the Phase 3 SPLASH Trial in mCRPC at ESMO Congress 2022
7:54am
8-K
EX-99.1
bkph7i9f1myhkgssgy8
6 Sep 22
POINT Biopharma Announces Poster Presentation at ESMO Congress 2022 Containing Efficacy & Safety Data from Lead-In Cohort of Phase 3 SPLASH Trial
8:11am
424B3
njjijy c0kx
11 Jul 22
Prospectus supplement
4:32pm
POS AM
nvjlgan
1 Jul 22
Prospectus update (post-effective amendment)
4:17pm
424B3
EX-99.1
xpjjypwv
16 May 22
Prospectus supplement
8:27am